Home » Business News » 2011 » June » June 9, 2011

Biopharmaceuticals Drive Adoption of Healthy Technologies -- Insight on Cell Therapeutics, Inc. and Pacific Biomarkers, Inc.

June 9, 2011 - Beijing

Today, announced its research report highlighting Cell Therapeutics, Inc. (NASDAQ: CTICD) and Pacific Biomarkers, Inc. (OTCBB: PBMC). Full report download is available at

Several new innovations within the health care field have revealed the influx of new interest to the Industry. Longer term, it is expected that a wider acceptance of biomarker research and genetic-targeted clinical studies to help shorten the development timeline and limit expenses. It is viewed that therapeutics for cancer, infectious diseases, autoimmune and inflammatory treatments are primary growth areas. The global medical industry is one of the world's fastest growing industries, absorbing over 10% of GDP of most developed nations.

Global Equity is reporting on Cell Therapeutics, Inc. (CTI) because it develops, acquires and commercializes treatments for cancer. It focuses on building a biopharmaceutical company with a diversified portfolio of oncology drugs. The company recently released the results of studies of two of its drugs Monday at an oncology convention in Chicago, saying one had "very encouraging" results and the other had "encouraging interim results." The full report and profile on Cell Therapeutics, Inc. (NASDAQ: CTICD) is available here:

Global Equity Reporter brings Pacific Biomarkers, Inc. forward as a provider of specialty laboratory services to support pharmaceutical, biotechnology and laboratory diagnostic manufacturers in the conduct of human clinical research, for use in their drug and diagnostic product development efforts. The company recently had an article featured in the May/June 2011 issue of IVD Technology magazine titled "A Kidney Injury Biomarker Initiative." Timothy H. Carlson, PhD, states, "The Company expects to be the leader in this field." The full report and profile on Pacific Biomarkers, Inc. (OTCBB: PBMC) is available here:

About Global Equity Reporter
Global Equity Reporter is a premier source for microcap research - providing a wide range of due diligence and investment insight on stocks all over the market Global Equity Reporter's primary focus is to alert our valued subscribers to small cap and microcap companies poised for explosive movement in the market. As every investor knows, timing in the market is critical, and that's where Global Equity Reporter delivers.


Alexander Griffin
Email Contact


Comment on this story